ClinicalTrials.gg
Not yet recruitingNCT03899298Updated Aug 22, 2019

Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions

A Phase 1 interventional study of Amniotic and Umbilical Cord Tissue Procedure in Orthopedic Disorder, Neurologic Disorder and Urologic Diseases, sponsored by R3 Stem Cell. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-22.

Primary conditionArthritisRegistry: Musculoskeletal DiseasesReclassifiedWhy we changed it
Registry
Musculoskeletal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis
Why
  1. The study's listed conditions name Arthritis, a narrower term within Musculoskeletal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by R3 Stem Cell · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.

Read the detailed description

The study will be ongoing for patient inclusion and data acquisition. Patients who have Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions will be included.

The study has been approved by an Alion accredited Institutional Review Board, Solutions IRB, as of March 2019.

Depending on the condition, patients may receive a series of therapies via one or more of the following methods: intravenous, injection, intra-nasal and/or nebulizer. R3 has several "best practice" therapy protocols that participating practices will follow. Should a patient have conditions that fall into more than one condition category, he or she can still be included with the protocols being received for each condition(s).

Here is a specific administration for each condition category:

  1. Orthopedic Condition = Injection
  2. Neurologic Disease = IV Infusion and Intranasal Procedure. The exception is with Peripheral Neuropathy, where participants receive a series of injections along with an IV Infusion Procedure.
  3. Urologic = Injection
  4. Autoimmune = IV Infusion
  5. Cardiac = IV Infusion
  6. Pulmonary = IV Infusion plus Nebulizer
  7. Renal = IV Infusion

Pre, Intra and Post procedure data acquisition will occur at various time frames up to 10 years. Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months and then on average each year, up to 10 years. Patients will pay for procedures, and no randomization will occur.

02

Conditions studied

  • Orthopedic Disorder
  • Neurologic Disorder
  • Urologic Diseases
  • Erectile Dysfunction
  • Autoimmune Diseases
  • Renal Failure
  • Renal Insufficiency
  • Kidney Diseases
  • Cardiac Event
  • Cardiomyopathies
  • CHF
  • Pulmonary Disease
  • COPD
  • Alzheimer Disease
  • Stroke
  • Neuropathy;Peripheral
  • Arthritis

Keywords

  • stem cell therapy
  • umbilical stem cells
  • amniotic stem cells
  • stem cells
  • regenerative medicine
  • r3 stem cell
  • perinatal tissue
  • placenta stem cell
03

In context

Arthritis Reclassified

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 97 across 599 interventional studies indexed under Arthritis.

Browse Arthritis studies →

Lead sponsor

R3 Stem Cell is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Arthritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Musculoskeletal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 and over.
  2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.
  3. Competent to understand the study protocol and provide voluntary .
  4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back/Neck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, , Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.

Exclusion criteria

Exclusion Criteria:

  1. Active Cancer
  2. Pregnancy, Lactating
  3. Severe Clotting disorder
  4. Myocardial Infarction less than six months ago.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    Amniotic and Umbilical Cord Tissue for Autoimmune Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

  • Experimental
    Amniotic and Umbilical Cord Tissue for Orthopedic Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

  • Experimental
    Amniotic and Umbilical Cord Tissue for Neurologic Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

  • Experimental
    Amniotic and Umbilical Cord Tissue for Urologic Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

  • Experimental
    Amniotic and Umbilical Cord Tissue for Cardiac Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

  • Experimental
    Amniotic and Umbilical Cord Tissue for Renal Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

  • Experimental
    Amniotic and Umbilical Cord Tissue for Pulmonary Conditions

    Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.

    Biological: Amniotic and Umbilical Cord Tissue Procedure

Interventions

  • BiologicalAmniotic and Umbilical Cord Tissue Procedure

    Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.

    Also known as: Amniotic and Umbilical Cord Tissue Infusion, Amniotic and Umbilical Cord Tissue Nebulizer, Amniotic and Umbilical Cord Tissue Injection, Amniotic and Umbilical Cord Tissue Intranasal

06

What researchers measure

Primary outcomes

  1. Disabilities of Arm, Shoulder, Hand Questionnaire (DASH)

    Upper Extremity Outcome Instrument

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  2. Sexual Health Inventory for Men Questionnaire (SHIM)

    Erectile Function Questionnaire. Scoring exists from 0 to 25. The lower the score, the more severe the Erectile Dysfunction.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  3. Kidney Disease and Quality of Life Questionnaire (KDQOL)

    Renal Function Outcome Instrument. Raw, precoded numeric values for 36 items are transformed linearly to a 0 to 100 range, with higher scores reflecting better quality of life.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  4. Assessment of Quality of Life Questionnaire (AQOL)

    General Health Outcome Instrument. Each instrument is used to derive a simple psychometric score for health related quality of life (HRQoL) and to provide profile scores on the different dimensions or items of the descriptive systems. The score is derived by adding the unweighted response order of each question, with a lower score denoting a better quality of life.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  5. Clinical Chronic Obstructive Pulmonary Disease Questionnaire

    COPD Outcome Instrument. Items are scored on a Likert scale (range 0-60). Higher scores indicate a worse health status.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  6. Mini Mental State Examination (MMSE)

    Memory Outcome Instrument. The maximum MMSE score is 30 points. The lower the score, the more severe the dementia.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  7. O'Leary/Sant Questionnaire

    Voiding and Pain Indices. Possible score of 0-20 with higher scores denoting better function.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  8. Oswestry Low Back Pain Disability Questionnaire

    Low Back Pain Outcome Instrument. Possible score of 0-100 with lower scores denoting better function.

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

  9. Western Ontario and McMaster Osteoarthritis Index (WOMAC)

    Arthritis Outcome Instrument. Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best).

    Time frame: Follow up time-frames will measure changes occurring from baseline post procedure at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months and 120 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No — Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2019; primary completion for Mar 2024, 54 months later.

Of 14 phase 1 interventional studies under Arthritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 54 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 2, 2019
StartEst.
Sep 1, 2019
Primary completionEst.
Mar 20, 2024
CompletionEst.
Mar 20, 2029
Last update
Aug 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03899298
Lead sponsor
R3 Stem Cell
Responsible party
Sponsor
First posted
Apr 2, 2019
Start date
Sep 1, 2019 (estimated)
Primary completion
Mar 20, 2024 (estimated)
Completion
Mar 20, 2029 (estimated)
Last update
Aug 22, 2019

Study contacts

David L Greene, MD, MBA
Contact
info@r3stemcell.com
(844) 438-7836
David Greene, MD, MBA
study director · R3 Stem Cell

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion